Compare EW & NDAQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EW | NDAQ |
|---|---|---|
| Founded | 1958 | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.1B | 54.9B |
| IPO Year | 1999 | 2001 |
| Metric | EW | NDAQ |
|---|---|---|
| Price | $86.37 | $93.27 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 29 | 18 |
| Target Price | $101.81 | ★ $108.75 |
| AVG Volume (30 Days) | ★ 3.4M | 2.8M |
| Earning Date | 11-04-2026 | 10-22-2026 |
| Dividend Yield | N/A | ★ 1.33% |
| EPS Growth | N/A | ★ 60.10 |
| EPS | 1.07 | ★ 1.80 |
| Revenue | ★ $6,067,600,000.00 | $4,277,000,000.00 |
| Revenue This Year | $11.45 | $12.46 |
| Revenue Next Year | $9.93 | $8.38 |
| P/E Ratio | $82.36 | ★ $51.97 |
| Revenue Growth | ★ 11.55 | 7.87 |
| 52 Week Low | $74.43 | $76.55 |
| 52 Week High | $96.29 | $101.79 |
| Indicator | EW | NDAQ |
|---|---|---|
| Relative Strength Index (RSI) | 48.45 | 50.01 |
| Support Level | $82.05 | $87.63 |
| Resistance Level | $89.41 | $93.34 |
| Average True Range (ATR) | 2.07 | 1.67 |
| MACD | 0.20 | 0.19 |
| Stochastic Oscillator | 65.50 | 67.39 |
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its trading business (about 22.5% of sales), the company sells market and financial data to investors, offers Nasdaq-branded indexes, and lists companies through its capital access segment (42.5%). Nasdaq's newest segment, financial technology, was primarily constructed through the acquisitions of Verafin and Adenza and has expanded the company into capital management, financial crime, and regulatory compliance software (35%) as it seeks to become a diversified technology company.